<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18868" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Intestinal Carcinoid Cancer</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Krishnan</surname>
            <given-names>Mridula</given-names>
          </name>
          <aff>Creighton University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tuma</surname>
            <given-names>Faiz</given-names>
          </name>
          <aff>Central Michigan University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mridula Krishnan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Faiz Tuma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18868.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Carcinoid tumor refers to a well-differentiated neuroendocrine tumor (NET) that originates commonly in the gastrointestinal tract (about 55%) or in other locations such as the lung, kidneys, or ovaries. The exception to this includes pancreatic neuroendocrine tumors, which are a separate entity called PNET. This activity reviews the pathophysiology and presentation of intestinal carcinoids and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of carcinoids.</p></list-item><list-item><p>Review the presentation of an intestinal carcinoid.</p></list-item><list-item><p>Summarize the treatment for intestinal carcinoid.</p></list-item><list-item><p>Explain modalities to improve care coordination among interprofessional team members in order to improve outcomes for patients affected by intestinal carcinoid.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18868&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18868">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18868.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Carcinoid tumor refers to a well-differentiated neuroendocrine tumor (NET) that originates commonly in the gastrointestinal tract (about 55%) or in other locations such as the lung, kidneys, or ovaries. The exception to this includes pancreatic neuroendocrine tumors, which are a separate entity called PNET. The term Carcinoid is the old name of NET originating from the intestine, although many physicians are still using the term. The name was derived from the word "Karzinoide" to indicate the carcinoma-like appearance. It&#x000a0;was believed to carry no malignant potential. Our knowledge and management of NETs have significantly developed since then.</p>
      </sec>
      <sec id="article-18868.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact etiology of NET tumors is unknown. There are risk factors&#x000a0;associated with a&#x000a0;higher incidence of the tumor, such as a&#x000a0;family history of neuroendocrine tumors or endocrine neoplasia.<xref ref-type="bibr" rid="article-18868.r1">[1]</xref><xref ref-type="bibr" rid="article-18868.r2">[2]</xref><xref ref-type="bibr" rid="article-18868.r3">[3]</xref>&#x000a0;These tumors have been identified&#x000a0;in&#x000a0;various locations, including the lungs, bronchi, and gastrointestinal tract. Gastrointestinal NETS can be of&#x000a0;foregut (respiratory tract, thymus), midgut (jejunum, ileum, right colon, stomach, proximal duodenum), and hindgut (distal colon, rectum) origin.&#x000a0;NETs&#x000a0;of the midgut (jejunum, ileum, appendix, and cecum)&#x000a0;are associated with carcinoid syndrome.<xref ref-type="bibr" rid="article-18868.r4">[4]</xref><xref ref-type="bibr" rid="article-18868.r5">[5]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-18868.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>NETs are relatively rare tumors. But the incidence of intestinal&#x000a0;NETS is on the rise due to increased detection of these tumors on routine imaging for other purposes. Small intestinal carcinoids are mostly located in the ileal region, which is 60 cm from the ileocecal valve. Colonic NETs&#x000a0;are usually detected in elderly patients and are commonly located on the right side, particularly the cecum. Commonly, rectal carcinoids are incidentally discovered on imaging.<xref ref-type="bibr" rid="article-18868.r6">[6]</xref><xref ref-type="bibr" rid="article-18868.r7">[7]</xref><xref ref-type="bibr" rid="article-18868.r8">[8]</xref></p>
        <p>Colorectal NETs are more frequent in the Asia/Pacific region than in Europe.<xref ref-type="bibr" rid="article-18868.r9">[9]</xref>&#x000a0;In Europe, small intestinal and stomach carcinoids are more prevalent. Intestinal NETs&#x000a0;have also been found to be more prevalent among African Americans as compared to whites.<xref ref-type="bibr" rid="article-18868.r10">[10]</xref>&#x000a0;The most common age group of gastrointestinal NETs presentation is the seventh decade and the median age&#x000a0;s 63 years.&#x000a0;</p>
      </sec>
      <sec id="article-18868.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Many&#x000a0;secretory products have been identified in various intestinal NETs. The most commonly produced substances include&#x000a0;serotonin, histamine, tachykinins, kallikrein, and prostaglandins.<xref ref-type="bibr" rid="article-18868.r11">[11]</xref>&#x000a0;When these substances are in systemic circulation, they cause a spectrum of symptoms called Carcinoid syndrome. Not All carcinoid tumors cause carcinoid syndrome.</p>
        <p>The metabolism of tryptophan is impaired in these patients with intestinal carcinoids. In a healthy individual, only 1% of tryptophan is converted into serotonin, whereas, in a patient with carcinoid, the&#x000a0;majority of tryptophan is metabolized to serotonin. This&#x000a0;serotonin&#x000a0;is excreted in the urine as 5-hydroxy indole acetic acid (5-HIAA).<xref ref-type="bibr" rid="article-18868.r12">[12]</xref>&#x000a0;Carcinoid syndrome results from hepatic metastasis or tumor location bypassing the portal circulation, as in retroperitoneal&#x000a0;or ovarian tumors.</p>
      </sec>
      <sec id="article-18868.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>NET tumors arise from enterochromaffin cells, also called Kulchitsky cells.<xref ref-type="bibr" rid="article-18868.r13">[13]</xref>&#x000a0;These cells&#x000a0;are&#x000a0;considered&#x000a0;neural crest cells at the crypts of&#x000a0;Lieberk&#x000fc;hn. The tumor&#x000a0;is classified&#x000a0;into three grades according to histopathologic aggressiveness. Grade 1 (Low grade), Grade 2 (intermediate grade), and Grade 3 (high grade). The classification is based&#x000a0;on&#x000a0;appearance, mitotic rates, behavior (invasion of other organs, angioinvasion), and Ki-67 proliferative index. The distinction between well and poorly-differentiated tumors is by far the most important; G1 and G2 tumors are considered well-differentiated, and G3 tumors are poorly differentiated. The use of the word "carcinoid" to describe primary intestinal NETs is considered&#x000a0;obsolete, although many clinicians continue to use this term. Certainly, it remains standard nomenclature to continue to refer to the syndrome as&#x000a0;carcinoid&#x000a0;syndrome.</p>
      </sec>
      <sec id="article-18868.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The clinical picture of carcinoid syndrome is caused by the mechanical effect of the tumor, like any other GI tumor, and or the secreted hormones from the tumor<xref ref-type="bibr" rid="article-18868.r14">[14]</xref>. Autonomic excitatory symptoms of the secreted hormones are occasionally identified and serve as a clue for the diagnosis.&#x000a0;Small bowel NET can cause chronic or recurrent abdominal pain and may occasionally lead to small bowel obstruction<xref ref-type="bibr" rid="article-18868.r4">[4]</xref>.</p>
        <p>In most cases, carcinoids may go unrecognized as patients may be asymptomatic until the advanced stages. It may manifest&#x000a0;with secretory clinical symptoms in the presence of liver metastasis. Uncommonly, carcinoid of the ovary or kidneys may clinically manifest as carcinoid syndrome&#x000a0;even in the absence of metastasis.</p>
        <p>The typical history given by patients includes gastrointestinal symptoms such as diarrhea and abdominal cramping<xref ref-type="bibr" rid="article-18868.r11">[11]</xref>. Dermatological symptoms commonly manifest as flushing due to histamine release. Occasional signs include the&#x000a0;presence of&#x000a0;telangiectasias. Other systemic symptoms may also include wheezing as a result of bronchoconstriction due to the release of histamine by the tumor. Also, some tumors may secrete other peptide hormones such as insulin, glucagon, vasoactive intestinal peptide (VIP), secretin, or gastrin which may produce other clinical manifestations.</p>
      </sec>
      <sec id="article-18868.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Intestinal NETs are rare and slow-growing tumors. They infrequently pose a diagnostic challenge to physicians. A high index of suspicion should be maintained for intestinal symptoms that are not well explained otherwise. Once the tumor is suspected, work should be completed to verify and characterize the tumor. On occasions,&#x000a0;tumors are&#x000a0;found incidentally&#x000a0;during work or surgery for other reasons. Once suspected, the following &#x000a0;tests may aid the diagnosis:</p>
        <p>
<bold>Laboratory Testing</bold>
</p>
        <p>A useful initial diagnostic test for carcinoid syndrome is 24 hours urinary excretion of 5-hydroxy indole acetic acid (5-HIAA). It has 90% sensitivity and specificity for the diagnosis of intestinal carcinoids. This may be falsely positive as a result of the ingestion of certain drugs or serotonin-rich foods. Other less commonly used tests&#x000a0;include chromogranin A concentration and measuring urinary excretion of serotonin.<xref ref-type="bibr" rid="article-18868.r1">[1]</xref></p>
        <p>
<bold>Imaging</bold>
</p>
        <p>Once the biochemical assessment of carcinoid disease is completed, imaging studies in combined modalities facilitate tumor localization.<xref ref-type="bibr" rid="article-18868.r13">[13]</xref> Various modalities have been used to detect intestinal carcinoids, including CT, MRI, and radiolabelled scans such as octreotide scan and gallium 68 DOTATATE scan<xref ref-type="bibr" rid="article-18868.r15">[15]</xref>.</p>
        <p>Triple phase contrast-enhanced CT scan is most commonly used as it is widely available. CT scan sensitivity is low (50%).&#x000a0;Some of the disadvantages of a CT scan are difficulty in detecting small tumors less than 1 cm in size and difficulty in distinguishing colorectal adenocarcinoma from colorectal carcinoid tumors due to their similarity in appearance.&#x000a0;CT scan increases significantly&#x000a0;with large or locally advanced tumors with mesenteric involvement with characteristic radiating dense soft tissue strands caused by thickened neurovascular bundles. Likewise, abdominal CT is thought to be helpful in identifying liver metastases. MRI modality is the most sensitive technique to detect liver metastasis and can be used as&#x000a0;an alternative to a CT scan.<xref ref-type="bibr" rid="article-18868.r15">[15]</xref></p>
        <p>Octreotide scan has the advantage of detecting metastasis beyond the abdominal region. It is currently&#x000a0;in use in conjunction&#x000a0;with Positron emission tomography (PET) scanning to increase sensitivity to detect pathologic uptake in the abdominal region.&#x000a0;Octreoscan&#x000a0;diagnostic sensitivity in asymptomatic patients with gastrointestinal NE tumors has been estimated to be in the range of 80% to 90%.<xref ref-type="bibr" rid="article-18868.r16">[16]</xref>&#x000a0;For surveillance, the clinical value of the octreotide scan of patients with carcinoid is questionable due to the availability of highly sensitive CT scans.</p>
      </sec>
      <sec id="article-18868.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The goal of treating intestinal NETs is to achieve&#x000a0;symptom control, tumor growth control, and biochemical control.<xref ref-type="bibr" rid="article-18868.r13">[13]</xref>&#x000a0;This can only be achieved&#x000a0;through a multidisciplinary approach and multi-modality&#x000a0;treatment. The treatment can be based on the extent of the disease.&#x000a0;</p>
        <p>
<bold>Treatment of Non-metastatic Intestinal Carcinoid</bold>
</p>
        <p>Treatment of localized disease is surgical resection with a&#x000a0;negative margin.&#x000a0;Surgery is the mainstay of treatment and the only way to achieve a complete cure for primary intestinal&#x000a0;NET. However, most patients have either synchronous metastatic tumors or liver metastasis at the time of presentation due to the indolent nature of the tumor.</p>
        <p>The extent of surgical resection depends on the size, location, and local spread of the disease. The same principle of loco-regional control used in the surgical treatment of midgut malignancies&#x000a0;is followed. A small tumor of 1 cm size can be locally excised. This is particularly&#x000a0;important in duodenal tumors where wider resection and pancreaticoduodenectomy&#x000a0;can be avoided.&#x000a0;Carcinoids of the small intestine have a high likelihood of metastasis, irrespective of size. Therefore, patients without evidence of metastasis should be treated with resection of the involved area of the small bowel, including the small bowel mesentery, with curative intent. Colorectal carcinoid tumors are mostly more than 2 cm and are invasive. Patients without metastasis should be treated with partial colectomy and lymphadenectomy. When presented with complications like bowel obstruction, surgical treatment is indicated primarily&#x000a0;to relieve the bowel obstruction on an urgent basis. Segmental bowel resection with the involved mesentery and primary anastomosis is sufficient treatment for primary control and complication relief.<xref ref-type="bibr" rid="article-18868.r15">[15]</xref></p>
        <p>
<bold>Treatment of Metastatic Intestinal Carcinoid</bold>
</p>
        <p>For patients with symptomatic carcinoid syndrome and unresectable disease, initial treatment is advised with a somatostatin analog. However, for patients with metastatic disease that is&#x000a0;resectable without extrahepatic metastases, cytoreductive&#x000a0;surgical&#x000a0;resection is preferred over medical therapy. Surgical treatment of&#x000a0;tumor-related&#x000a0;complications is&#x000a0;indicated to control the complications.</p>
        <p>Medical Management:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Somatostatin analogs: These are first-line agents used for the treatment of symptomatic carcinoids.&#x000a0;Right-sided includes octreotide and lanreotide, which have been shown to be highly effective in&#x000a0;controlling symptoms of intestinal carcinoids. A depot preparation of octreotide is available in the form of monthly intramuscular injections. These are usually well-tolerated except for mild symptoms such as nausea or bloating.</p>
          </list-item>
          <list-item>
            <p>Interferon: This may be an option for patients with&#x000a0;advanced disease who have worsening symptoms while on treatment with somatostatin analogs or who are intolerant of somatostatin analog therapy, but it is less commonly used due to potentially adverse effects.</p>
          </list-item>
          <list-item>
            <p>Molecular-directed therapy: mTor inhibitors like everolimus are&#x000a0;currently&#x000a0;approved as second-line therapy for patients who have progressive symptoms despite the use of somatostatin analogs.</p>
          </list-item>
        </list>
        <p>
<bold>Treatment of Hepatic Metastasis</bold>
</p>
        <p>Surgical liver resection in patients with hepatic metastasis has a role in symptom relief and survival rate improvement.<xref ref-type="bibr" rid="article-18868.r17">[17]</xref>&#x000a0;Therefore, when a&#x000a0;resectable hepatic metastasis is identified, appropriate liver resection should be considered as part of the surgical planning.&#x000a0;</p>
      </sec>
      <sec id="article-18868.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Crohn disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ileus</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Small intestinal diverticulosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ulcerative colitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18868.s11" sec-type="Staging">
        <title>Staging</title>
        <p>
<bold>Staging</bold>
</p>
        <p>The current TNM staging system is a combined staging for jejunoileal, duodenal, and ampullary neuroendocrine tumors. In the United States,&#x000a0;the newer version&#x000a0;has separate TNM classifications and prognostications for jejunoileal and&#x000a0;duodenal/ampullary&#x000a0;tumors.<xref ref-type="bibr" rid="article-18868.r18">[18]</xref><xref ref-type="bibr" rid="article-18868.r19">[19]</xref><xref ref-type="bibr" rid="article-18868.r15">[15]</xref></p>
      </sec>
      <sec id="article-18868.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>NETs are slow growing, indolent tumors. But they induce the same other consequences of uncontrolled tumor growth with mechanical and physiologic alteration of the gastrointestinal tract. Bowel obstruction, perforation, bleeding, and altered function are possible complications of advanced intestinal NETs. Therefore, prognosis depends primarily on the tumor and disease stage, tumor location, presence of metastasis, presence of synchronous or metachronous&#x000a0;tumors, and histologic&#x000a0;grade/differentiation. Overall, the&#x000a0;prognosis of intestinal carcinoids is good. High overall&#x000a0;survival rates were&#x000a0;reported&#x000a0;among&#x000a0;intestinal NETs&#x000a0;patients, including patients with distant metastasis with a 5-year overall survival range between 40% to 85%.<xref ref-type="bibr" rid="article-18868.r20">[20]</xref><xref ref-type="bibr" rid="article-18868.r21">[21]</xref></p>
      </sec>
      <sec id="article-18868.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>
<bold>Surveillance</bold>
</p>
        <p>There is&#x000a0;limited evidence for recommendations for follow-up after surgical resection. For all resected small intestinal and colonic carcinoid tumors, follow long-term surveillance as there is a risk of recurrence even 5 years following resection. For small intestinal carcinoids, the general recommendation for surveillance is with triple-phase CT or MRI imaging. Tumors less than 2 cm in size are less likely to metastasize. Urine 5-HIAA and chromogranin A are followed every six months for the first couple of years. This is followed by annual surveillance for four years, followed by every 2 years up to 10 years after surgery.</p>
      </sec>
      <sec id="article-18868.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The North American Neuroendocrine Tumor Society has released guidelines for the management of midgut neuroendocrine tumors. The guidelines&#x000a0;emphasize an interprofessional approach for optimal outcomes. While surgery is the ideal treatment for patients with localized lesions, recent studies reveal that cytoreductive surgery with heated intraperitoneal&#x000a0;chemotherapy may improve&#x000a0;survival in some patients with metastatic&#x000a0;peritoneal disease. Because these tumors have unpredictable behavior, lifelong surveillance is&#x000a0;recommended. With expert care, many patients can have a good quality of life or even be cured.&#x000a0;<xref ref-type="bibr" rid="article-18868.r22">[22]</xref><xref ref-type="bibr" rid="article-18868.r23">[23]</xref><xref ref-type="bibr" rid="article-18868.r24">[24]</xref>&#x000a0;[Level 5] A team of&#x000a0;general&#x000a0;surgery,&#x000a0;medical&#x000a0;oncology, diagnostic radiology, endoscopy, pharmaceutical expertise, and nursing care&#x000a0;should be available to participate in the care of this patient.&#x000a0;<xref ref-type="bibr" rid="article-18868.r25">[25]</xref>&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-18868.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18868&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18868">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/intestinal-carcinoid-cancer/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=18868">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18868/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18868">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18868.s16">
        <title>References</title>
        <ref id="article-18868.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strosberg</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Halfdanarson</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Bellizzi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dillon</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Heaney</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Kunz</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>O'Dorisio</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Salem</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Segelov</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Howe</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Pommier</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Brendtro</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bashir</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soulen</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zacks</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Bergsland</surname>
                <given-names>EK</given-names>
              </name>
            </person-group>
            <article-title>The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.</article-title>
            <source>Pancreas</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>46</volume>
            <issue>6</issue>
            <fpage>707</fpage>
            <page-range>707-714</page-range>
            <pub-id pub-id-type="pmid">28609356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campana</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ravizza</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferolla</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Faggiano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grimaldi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Albertelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ricci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Santini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brighi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fazio</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Colao</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferone</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tomassetti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study.</article-title>
            <source>Endocrine</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>56</volume>
            <issue>3</issue>
            <fpage>633</fpage>
            <page-range>633-638</page-range>
            <pub-id pub-id-type="pmid">27592118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rinzivillo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Capurso</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Campana</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fazio</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Panzuto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Spada</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cicchese</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Partelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tomassetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Falconi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Delle Fave</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study.</article-title>
            <source>Neuroendocrinology</source>
            <year>2016</year>
            <volume>103</volume>
            <issue>5</issue>
            <fpage>531</fpage>
            <page-range>531-7</page-range>
            <pub-id pub-id-type="pmid">26356731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bla&#x0017e;evi&#x00107;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Feelders</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum.</article-title>
            <source>Endocr Relat Cancer</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>R115</fpage>
            <page-range>R115-R130</page-range>
            <pub-id pub-id-type="pmid">29233841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ro</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Recent updates on grading and classification of neuroendocrine tumors.</article-title>
            <source>Ann Diagn Pathol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>29</volume>
            <fpage>11</fpage>
            <page-range>11-16</page-range>
            <pub-id pub-id-type="pmid">28807335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daskalakis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsolakis</surname>
                <given-names>AV</given-names>
              </name>
            </person-group>
            <article-title>Upfront surgery of small intestinal neuroendocrine tumors. Time to reconsider?</article-title>
            <source>World J Gastroenterol</source>
            <year>2018</year>
            <month>Aug</month>
            <day>07</day>
            <volume>24</volume>
            <issue>29</issue>
            <fpage>3201</fpage>
            <page-range>3201-3203</page-range>
            <pub-id pub-id-type="pmid">30090001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moris</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tsilimigras</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Vagios</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ntanasis-Stathopoulos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Karachaliou</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Papalampros</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alexandrou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blazer</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Felekouras</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Neuroendocrine Neoplasms of the Appendix: A Review of the Literature.</article-title>
            <source>Anticancer Res</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>601</fpage>
            <page-range>601-611</page-range>
            <pub-id pub-id-type="pmid">29374682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alexandraki</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Karapanagioti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karoumpalis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Boutzios</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.</article-title>
            <source>Biomed Res Int</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>9856140</fpage>
            <pub-id pub-id-type="pmid">29349087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.</article-title>
            <source>BMC Endocr Disord</source>
            <year>2017</year>
            <month>Jul</month>
            <day>13</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <pub-id pub-id-type="pmid">28705205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strosberg</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Neuroendocrine tumours of the small intestine.</article-title>
            <source>Best Pract Res Clin Gastroenterol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>755</fpage>
            <page-range>755-73</page-range>
            <pub-id pub-id-type="pmid">23582917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boutzios</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Clinical Syndromes Related to Gastrointestinal Neuroendocrine Neoplasms.</article-title>
            <source>Front Horm Res</source>
            <year>2015</year>
            <volume>44</volume>
            <fpage>40</fpage>
            <page-range>40-57</page-range>
            <pub-id pub-id-type="pmid">26303703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porter</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Stoeger</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Atypical Colorectal Neoplasms.</article-title>
            <source>Surg Clin North Am</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>97</volume>
            <issue>3</issue>
            <fpage>641</fpage>
            <page-range>641-656</page-range>
            <pub-id pub-id-type="pmid">28501252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinchot</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Holen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sippel</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Carcinoid tumors.</article-title>
            <source>Oncologist</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>12</issue>
            <fpage>1255</fpage>
            <page-range>1255-69</page-range>
            <pub-id pub-id-type="pmid">19091780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matshela</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Cases in a series of carcinoid syndrome and carcinoid heart disease.</article-title>
            <source>Cardiovasc J Afr</source>
            <year>2018</year>
            <season>May/Jun</season>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>e1</fpage>
            <page-range>e1-e7</page-range>
            <pub-id pub-id-type="pmid">30204224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raphael</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Principles of diagnosis and management of neuroendocrine tumours.</article-title>
            <source>CMAJ</source>
            <year>2017</year>
            <month>Mar</month>
            <day>13</day>
            <volume>189</volume>
            <issue>10</issue>
            <fpage>E398</fpage>
            <page-range>E398-E404</page-range>
            <pub-id pub-id-type="pmid">28385820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Essen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sundin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krenning</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Kwekkeboom</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Neuroendocrine tumours: the role of imaging for diagnosis and therapy.</article-title>
            <source>Nat Rev Endocrinol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>102</fpage>
            <page-range>102-14</page-range>
            <pub-id pub-id-type="pmid">24322649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Landry</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Scoggins</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>McMasters</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Management of hepatic metastasis of gastrointestinal carcinoid tumors.</article-title>
            <source>J Surg Oncol</source>
            <year>2008</year>
            <month>Mar</month>
            <day>01</day>
            <volume>97</volume>
            <issue>3</issue>
            <fpage>253</fpage>
            <page-range>253-8</page-range>
            <pub-id pub-id-type="pmid">18264984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical outcomes of ligation-assisted endoscopic resection for duodenal neuroendocrine tumors.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>May</month>
            <volume>97</volume>
            <issue>18</issue>
            <fpage>e0533</fpage>
            <pub-id pub-id-type="pmid">29718844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwartz</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Forleiter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Occult Appendiceal Neoplasms in Acute and Chronic Appendicitis: A Single-Institution Experience of 1793 Appendectomies.</article-title>
            <source>Am Surg</source>
            <year>2017</year>
            <month>Dec</month>
            <day>01</day>
            <volume>83</volume>
            <issue>12</issue>
            <fpage>1381</fpage>
            <page-range>1381-1385</page-range>
            <pub-id pub-id-type="pmid">29336758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tierney</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Chivukula</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Pappas</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Schadde</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hertl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Poirier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keutgen</surname>
                <given-names>XM</given-names>
              </name>
            </person-group>
            <article-title>Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.</article-title>
            <source>Surgery</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>165</volume>
            <issue>3</issue>
            <fpage>644</fpage>
            <page-range>644-651</page-range>
            <pub-id pub-id-type="pmid">30366604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laskaratos</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wilkins</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tuck</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ramakrishnan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gertner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Megapanou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Papantoniou</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Banks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vlachou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Garcia-Hernandez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Woodbridge</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Papadopoulou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Theocharidou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Watkins</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Luong</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Mandair</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Caplin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toumpanakis</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Clinical Prognostic Factors and Further Delineation of the Effect of Mesenteric Fibrosis on Survival in Advanced Midgut Neuroendocrine Tumours.</article-title>
            <source>Neuroendocrinology</source>
            <year>2018</year>
            <volume>107</volume>
            <issue>3</issue>
            <fpage>292</fpage>
            <page-range>292-304</page-range>
            <pub-id pub-id-type="pmid">30153671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pasricha</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Padhi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Daboul</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Monga</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.</article-title>
            <source>Clin Ther</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>39</volume>
            <issue>11</issue>
            <fpage>2146</fpage>
            <page-range>2146-2157</page-range>
            <pub-id pub-id-type="pmid">29173655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shenoy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Goblet cell carcinoids of the appendix: Tumor biology, mutations and management strategies.</article-title>
            <source>World J Gastrointest Surg</source>
            <year>2016</year>
            <month>Oct</month>
            <day>27</day>
            <volume>8</volume>
            <issue>10</issue>
            <fpage>660</fpage>
            <page-range>660-669</page-range>
            <pub-id pub-id-type="pmid">27830037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Solorzano</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Katznelson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vinik</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Randolph</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids.</article-title>
            <source>Endocr Pract</source>
            <year>2015</year>
            <month>May</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>534</fpage>
            <page-range>534-545</page-range>
            <pub-id pub-id-type="pmid">25962092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18868.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000d6;berg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lamberts</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.</article-title>
            <source>Endocr Relat Cancer</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>23</volume>
            <issue>12</issue>
            <fpage>R551</fpage>
            <page-range>R551-R566</page-range>
            <pub-id pub-id-type="pmid">27697899</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
